Business

Teva Pharmaceutical has acquired privately held Gecko Health Innovations and its CareTRx asthma and COPD management system. CareTRx works with a monitoring device called GeckoCap that attaches to an MDI plus a mobile phone app. The acquisition comes two months after AstraZeneca announced a partnership with inhaler monitoring company Adherium. Gecko Founder and CEO … [Read more...] about Teva acquires Gecko Health Innovations

Inhaled drug developer Alexza Pharmaceuticals has hired a financial advisor "to assist in exploring strategic options to enhance stockholder value," the company said. Options being explored include selling corporate assets, a strategic business combination, or a partnership. Earlier this year, Alexza announced that it would suspend manufacturing of Adasuve inhaled … [Read more...] about Alexza considers “strategic options to enhance stockholder value”

Natesto intranasal testosterone developer Trimel Pharmaceuticals Corporation has announced that it has a new name: Acerus Pharmaceuticals Corporation. Acerus President and CEO Tom Rossi commented, “We are very excited to officially launch our new corporate identity with a name that aligns to our Company’s value proposition. The name Acerus is derived from the … [Read more...] about Trimel Pharmaceuticals changes its name to Acerus

Invion Limited, which is developing several inhaled drugs, has announced a private placement in which it is issuing 71.5 million ordinary shares at $0.014 per share to "a US institutional investor" for a total of about A$1 million. The company says that it will use the proceeds for working capital. Invion Managing Director and CEO Greg Collier commented, "Invion is … [Read more...] about Invion raises A$1 million through private placement

Aegis Therapeutics has announced that it received its first Russian patent (No. 2554814), titled, “Compositions for drug administration.” The patent covers formulations of triptans for the treatment of migraine that use Aegis’ Intravail transmucosal absorption enhancers. According to the company, the Intravail formulation results in the achievment of clinically … [Read more...] about Aegis Therapeutics gets patents for intranasal delivery of triptans

Israeli biopharmaceutical company Advanced Inhalation Therapies (AIT), which recently received orphan drug status in Europe for its inhaled nitric oxide for the treatment of cystic fibrosis, has filed with the US Securities and Exchange Commission (SEC) for an initial public offering. The company is looking to raise up to $36 million to support Phase 2 development of … [Read more...] about Advanced Inhalation Therapies files for IPO

Skyepharma has reported that in-market sales of the flutiform fluticasone/formoterol MDI for the first 6 months of 2015 have totaled €65.1 million, up from €28.4 million in the first half of 2014, and the directors now predict that flutiform revenues will exceed previous expectations for the year. Skyepharma CEO Peter Grant commented, ""With a strong start to the … [Read more...] about Skyepharma reports revenues from flutiform have risen significantly

Raptor Pharmaceutical Co. plans to launch Quinsair inhaled levofloxacin inhalation solution in Europe and Canada by mid-2016, the company said after announcing that it has agreed to pay Tripex Pharmaceuticals $68.4 million upfront and up to $350 million in milestone payments and royalties to acquire global rights to the product. Quinsair (formerly Aeroquin) was … [Read more...] about Raptor Pharmaceutical acquires Quinsair levofloxacin inhalation solution